Efficacy and safety of direct oral anticoagulants in children in real clinical practice ; Эффективность и безопасность применения прямых пероральных антикоагулянтов у детей в реальной клинической практике

Authors: T. Yu. Yafoshkina, Yu. A. Shifrin, D. V. Fedorova, D. B. Florinskiy, D. A. Evstratov, P. A. Zharkov, Т. Ю. Яфошкина, Ю. А. Шифрин, Д. В. Федорова, Д. Б. Флоринский, Д. А. Евстратов, П. А. Жарков

Source: Russian Journal of Pediatric Hematology and Oncology; Том 10, № 1 (2023); 33-40 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 10, № 1 (2023); 33-40 ; 2413-5496 ; 2311-1267

Subject Terms: новые пероральные антикоагулянты, thrombosis therapy, thrombosis in children, anticoagulants, new oral anticoagulants, терапия тромбозов, тромбозы у детей, антикоагулянты

File Description: application/pdf

Relation: https://journal.nodgo.org/jour/article/view/919/813; Raffini L., Huang Y.S., Witmer C., Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001–8. doi:10.1542/peds.2009-0768.; Федеральные клинические рекомендации по диагностике, профилактике и лечению тромбозов у детей и подростков. М., 2015.; [Электронный ресурс]. URL: https://www.uptodate.com/contents/venous-thrombosis-and-thromboembolism-vte-in-children-riskfactors-clinical-manifestations-and-diagnosis. (Дата обращения: 14.09.2022).; De Crem N., Peerlinck K., Vanassche T., Vanheule K., Debaveye B., Middeldorp S., Verhamme P., Peetermans M. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res. 2015;136(4):749–53. doi:10.1016/j.thromres.2015.07.030.; Kaatz S., Ahmad D., Spyropoulos A.C., Schulman S.; Subcommittee on Control of Anticoagulation. Definition of clinically relevant nonmajor bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(11):2119–26. doi:10.1111/jth.13140.; [Электронный ресурс]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=073cdf44-10f6-4fa4-ab24-a5727d8c90f5. (Дата обращения: 17.01.2023).; Halton J., Brandão L.R., Luciani M., Bomgaars L., Chalmers E., Mitchell L.G., Nurmeev I., Sharathkumar A., Svirin P., Gorbatikov K., Tartakovsky I., Simetzberger M., Huang F., Sun Z., Kreuzer J., Gropper S., Reilly P., Brueckmann M., Albisetti M.; DIVERSITY Trial Investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021;8(1):e22–33. doi:10.1016/S2352-3026(20)30368-9.; Male C., Lensing A.W.A., Palumbo J.S., Kumar R., Nurmeev I., Hege K., Bonnet D., Connor P., Hooimeijer H.L., Torres M., Chan A.K.C., Kenet G., Holzhauer S., Santamaría A., Amedro P., Chalmers E., Simioni P., Bhat R.V., Yee D.L., Lvova O., BeyerWestendorf J., Biss T.T., Martinelli I., Saracco P., Peters M., Kállay K., Gauger C.A., Massicotte M.P., Young G., Pap A.F., Majumder M., Smith W.T., Heubach J.F., Berkowitz S.D., Thelen K., Kubitza D., Crowther M., Prins M.H., Monagle P.; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7(1):e18–27. doi:10.1016/S2352-3026(19)30219-4.; Bryk A.H., Piróg M., Plens K., Undas A. Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism. Vascul Pharmacol. 2016;87:242–7. doi:10.1016/j.vph.2016.11.003.; Bannow B.S. Management of heavy menstrual bleeding on anticoagulation. Hematology Am Soc Hematol Educ Program. 2020;2020(1):533–7. doi:10.1182/hematology.2020000138.; Limperger V., Torge A., Kiesau B., Langer F., Kenet G., Mesters R., Juhl D., Stoll M., Shneyder M., Kowalski D., Bajorat T., Rocke A., Kuta P., Lasarow L., Spengler D., Junker R., Nowak-Göttl U. Validation of a predictive model for identifying an increased risk for recurrence in adolescents and young adults with a first provoked thromboembolism. Blood Cells Mol Dis. 2022;94:102651. doi:10.1016/j.bcmd.2022.102651.; Brandão L.R., Albisetti M., Halton J., Bomgaars L., Chalmers E., Mitchell L.G., Nurmeev I., Svirin P., Kuhn T., Zapletal O., Tartakovsky I., Simetzberger M., Huang F., Sun Z., Kreuzer J., Gropper S., Brueckmann M., Luciani M.; DIVERSITY Study Investigators. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020;135(7):491–504. doi:10.1182/blood.2019000998.; Pinchinat A., Otero N., Mahanti H., Morris E., Brudnicki A., Friedman D., Li S., Levendoglu-Tugal O., Cairo M.S.; A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents. Blood. 2019;134(Suppl. 1):2443. doi:10.1182/blood-2019-130468.; O’Brien S., Rodriguez V., Lew G., Newburger J., Schultz C., Orgel E., Derr K., Ranalli M., Esbenshade A., Hochberg J., Kang H., Dinikina Y., Crevar C., Donovan M., Dyme J., Favatella N., Mitchell L. PREVAPIX-ALL: Phase 3 Study of the Safety and Efficacy of Apixaban for Thromboprophylaxis versus Standard of Care in Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia or Lymphoma (ALL/LL). [Электронный ресурс]. URL: https://abstracts.isth.org/abstract/prevapix-all-phase-3-study-of-the-safety-and-efficacy-ofapixaban-for-thromboprophylaxis-versus-standard-of-care-in-newlydiagnosed-pediatric-acute-lymphoblastic-leukemia-or-lymphoma-all-ll/. Accessed January 23, 2023.; McCrindle B.W., Michelson A.D., Van Bergen A.H., Horowitz E.S., Sandoval J.P., Justino H., Harris K.C., Jefferies J.L., Pina L.M., Peluso C., Nessel K., Lu W., Li J.S.; UNIVERSE Study Investigators. Thromboprophylaxis for children post-Fontan procedure: insights from the UNIVERSE study. J Am Heart Assoc. 2021;10(22):e021765. doi:10.1161/JAHA.120.021765.; Nowak-Göttl U., Junker R., Kreuz W., von Eckardstein A., Kosch A., Nohe N., Schobess R., Ehrenforth S.; Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood. 2001;97(4):858–62. doi:10.1182/blood.v97.4.858.; Goldenberg N.A., Pounder E., Knapp-Clevenger R., Manco-Johnson M.J. Validation of upper extremity post-thrombotic syndrome outcome measurement in children. J. Pediatr. 2010;157(5):852–5. doi:10.1002/rth2.12251.; Goldenberg N.A., Donadini M.P., Kahn S.R., Crowther M., Kenet G., Nowak-Göttl U., Manco-Johnson M.J. Post-thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica. 2010;95(11):1952–9. doi:10.3324/haematol.2010.026989.; Avila M.L., Feldman B.M., Pullenayegum E., Lumia C., Montoya M.I., Vincelli J., Williams S., Brandão L.R. Post-thrombotic syndrome in children: Measurement properties of CAPTSure, a new diagnostic tool. Res Pract Thromb Haemost. 2019;3(4):652–7. doi:10.1002/rth2.12251.; https://journal.nodgo.org/jour/article/view/919

Availability: https://journal.nodgo.org/jour/article/view/919
https://doi.org/10.21682/2311-1267-2023-10-1-33-40

Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis ; ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ НОВЫХ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ У БОЛЬНЫХ С ВЕНОЗНЫМИ ТРОМБОЭМБОЛИЧЕСКИМИ ОСЛОЖНЕНИЯМИ: МЕТА-АНАЛИЗ

Authors: V. Petrov I., O. Shatalova V., V. Gorbatenko S., O. Smuseva N., A. Maslakov S., В. Петров И., О. Шаталова В., В. Горбатенко С., О. Смусева Н., А. Маслаков С.

Source: Rational Pharmacotherapy in Cardiology; Vol 12, No 6 (2016); 31-39 ; Рациональная Фармакотерапия в Кардиологии; Vol 12, No 6 (2016); 31-39 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2016-12-6

Subject Terms: randomized clinical trials, meta-analysis, new oral anticoagulants, venous thromboembolism, рандомизированные контролируемые исследования, мета-анализ, новые пероральные антикоагулянты, венозные тромбоэмболические осложнения

File Description: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/1192/1220; Savelyev VS, Chazov EI, Gusev EI, et al. The Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic events. Flebologiia 2010; 4: 1-40. In Russian (Савельев В.С., Чазов Е.И. Гусев Е.И. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология 2010; 4: 1-40).; Heit J., Cohen A., Anderson F. et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood (ASH Annual Meeting Abstracts) 2005; 106: Abstract 910.; Cohen A., Agnelli G., Anderson F. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-64.; Spencer F., Emery C., Lessard D. et al. The Worcester Venous Thromboembolism study: a populationbased study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-7.; Cohen A., Dobromirski M. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thromb Haemost 2012; 107 (6): 1035-43.; Guidelines on the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology, 2014; Kearon C., Akl E., Comerota A. et al. Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2): S419-94.; Ansell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133: S160-98.; Moher D., Liberati A., Tetzlaff J., Altman D.G. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 2009; 3: 123-30.; Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-6.; Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.; DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.; Higgins J.P., Thompson S.G. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21: 1539- 58.; The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.; The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.; Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.; Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72.; Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (9): 799-808.; Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal 2013; 11:21.; https://www.rpcardio.com/jour/article/view/1192

Availability: https://www.rpcardio.com/jour/article/view/1192

Practical aspects of the use of apixaban, new oral anticoagulant, for stroke and trombembolia prevention

Authors: Skybchyk, V. A.

Source: Medicine of Ukraine; № 1-2(197-8) (2016); 16-20
Лекарства Украины; № 1-2(197-8) (2016); 16-20
Ліки України; № 1-2(197-8) (2016); 16-20

Subject Terms: нові пероральні антикоагулянти, антагоністи вітаміну К, неклапанна фібриляція передсердь, профілактика кардіоемболічного інсульту та тромбоемболії, новые пероральные антикоагулянты, антагонисты витамина К, неклапанная фибрилляция предсердий, профилактика кардиоэмболического инсульта и тромбоэмболии, new oral anticoagulants, vitamin K antagonists, non-valvular atrial fibrillation, cardioembolic stroke and trombembolia prevention, 616.831-005.1+616.1-005.6/.7(-085.273, 3. Good health

File Description: application/pdf

Access URL: http://lu-journal.com.ua/article/download/203287/203060
http://lu-journal.com.ua/article/view/203287

ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY

Authors: V. A. Sulimov, O. S. Anikina, A. A. Sokolova, Dmitry Napalkov, A. V. Jilenko

Source: Рациональная фармакотерапия в кардиологии, Vol 11, Iss 2, Pp 116-123 (2015)

Subject Terms: thromboembolic events, тромбоэмболические осложнения, новые пероральные антикоагулянты, RM1-950, 3. Good health, novel oral anticoagulants, vitamin k antagonists, антагонисты витамина К, 03 medical and health sciences, фибрилляция предсердий, 0302 clinical medicine, RC666-701, Diseases of the circulatory (Cardiovascular) system, atrial fibrillation, Therapeutics. Pharmacology

Access URL: https://www.rpcardio.com/jour/article/download/73/80
https://doaj.org/article/c2446d48b0cf4b799327dae1ea0dfc06
https://doaj.org/article/b548dc0e1f604b01ac4e05aaf063a1bb
https://www.rpcardio.com/jour/article/view/73
https://www.rpcardio.com/jour/article/download/73/80
https://core.ac.uk/display/87816852

PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST

Authors: I. I. Sinitsina, Dmitriy A. Sychev, G. Yu. Zakharova, M. I. Savel'eva, A. V. Kryukov, A. Yu. Yurovskii, A. V. Ryabova

Source: Рациональная фармакотерапия в кардиологии, Vol 11, Iss 2, Pp 209-216 (2015)

Subject Terms: drug-drug interactions, клиническая фармакология, новые пероральные антикоагулянты, апиксабан, new oral anticoagulants, apixaban, кровотечения, межлекарственное взаимодействие, perioperative management, RM1-950, bleeding, 3. Good health, 03 medical and health sciences, периоперацион-ное ведение, 0302 clinical medicine, RC666-701, Diseases of the circulatory (Cardiovascular) system, clinical pharmacology, Therapeutics. Pharmacology

Access URL: https://www.rpcardio.com/jour/article/download/154/156
https://doaj.org/article/66ccb771d501455f8b3489d168248d67
https://doaj.org/article/33dc2363659d4ebdbc2993f4515483ac
https://www.rpcardio.com/jour/article/view/154
https://www.rpcardio.com/jour/article/download/154/156
https://core.ac.uk/display/91369968

ON THE SELECTION OF DRUGS DOSAGE REGIMEN

Authors: E. N. Bochanova

Source: Рациональная фармакотерапия в кардиологии, Vol 11, Iss 1, Pp 92-95 (2015)

Subject Terms: 03 medical and health sciences, 0302 clinical medicine, режим дозирования, новые пероральные антикоагулянты, RC666-701, new oral anticoagulants, Diseases of the circulatory (Cardiovascular) system, dosage regimen, Therapeutics. Pharmacology, RM1-950, фармакокинетика, pharmacokinetics, 3. Good health

Access URL: https://www.rpcardio.com/jour/article/download/66/73
https://doaj.org/article/171ceb904c754e2689dbff97faf34db3
https://doaj.org/article/857b9895cc25474c8f7d589bfa3a52be
https://core.ac.uk/display/87816868
https://www.rpcardio.com/jour/article/download/66/73
https://www.rpcardio.com/jour/article/view/66

The main causes and current principles of prevention of cardioembolic stroke

Authors: A. V. Fonyakin, L. A. Geraskina

Source: Медицинский совет, Vol 0, Iss 12, Pp 78-83 (2015)

Subject Terms: кардиоэмболический инсульт, неклапанная фибрилляция предсердий, антикоагулянтная терапия, новые пероральные антикоагулянты, апиксабан, cardioembolic stroke, non-valvular atrial fibrillation, anticoagulation therapy, new oral anticoagulant, apixaban, Medicine

File Description: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/1616; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

Access URL: https://doaj.org/article/d31aca9f47124ffe97874ba769ba3d76

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA

Authors: D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev

Source: Рациональная фармакотерапия в кардиологии, Vol 9, Iss 5, Pp 525-531 (2015)

Subject Terms: антикоагулянты, варфарин, новые пероральные антикоагулянты, дабигатран, фармакогенетика, CYP2С9, VKORC1, CES1, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/220; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

Access URL: https://doaj.org/article/189a689a3a01454b92e9d312b92fd397

PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST

Authors: D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii

Source: Рациональная фармакотерапия в кардиологии, Vol 11, Iss 2, Pp 209-216 (2015)

Subject Terms: новые пероральные антикоагулянты, апиксабан, клиническая фармакология, межлекарственное взаимодействие, кровотечения, периоперацион-ное ведение, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/154; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

Access URL: https://doaj.org/article/66ccb771d501455f8b3489d168248d67

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION

Authors: A. V. Rudakova, V. A. Parfenov

Source: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 3, Pp 275-282 (2015)

Subject Terms: фибрилляция предсердий, новые пероральные антикоагулянты, анализ затраты-эффективность, апиксабан, варфарин, ацетилсалициловая кислота, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/233; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

Access URL: https://doaj.org/article/68dc57b562194a789db462f64a160da7

THE ASSESSMENT OF COMPLIANCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE PROFILE REGISTER

Authors: S. Y. Martsevich, A. R. Navasardyan, N. P. Kutishenko, A. V. Zakharova, V. P. Voronina, N. A. Dmitrieva, L. Yu. Lrozdova, A. V. Zagrebelnyy, O. V. Lerman, Yu. V. Lukina, G. V. Martynova, A. A. Nikulina, G. S. Ryazanova, A. Yu. Suvorov, S. N. Tolpygina

Source: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 6, Pp 625-630 (2015)

Subject Terms: фибрилляция предсердий, регистр, антитромботическая терапия, новые пероральные антикоагулянты, приверженность к приему препарата, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/295; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

Access URL: https://doaj.org/article/ea4476ebf61143adafeb10a74d518d3a

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION

Authors: E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko

Source: Рациональная фармакотерапия в кардиологии, Vol 9, Iss 5, Pp 551-556 (2015)

Subject Terms: фибрилляция предсердий, профилактика инсульта, новые пероральные антикоагулянты, дабигатрана этексилат, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/232; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

Access URL: https://doaj.org/article/5cc44adbbae74f068d1d2dfd33f7451a

THE ASSESSMENT OF COMPLIANCE TO THE USE OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION ACCORDING TO THE PROFILE REGISTER

Authors: Yu. V. Lukina, V. P. Voronina, N. A. Dmitrieva, S. Y. Martsevich, G. S. Ryazanova, N. P. Kutishenko, S. N. Tolpygina, A. R. Navasardyan, A. Yu. Suvorov, L. Yu. Lrozdova, A. V. Zagrebelnyy, A. V. Zakharova, G. V. Martynova, O. V. Lerman, A. A. Nikulina

Source: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 6, Pp 625-630 (2015)

Subject Terms: register, новые пероральные антикоагулянты, new oral anticoagulants, antithrombotic therapy, приверженность к приему препарата, RM1-950, 7. Clean energy, 3. Good health, 03 medical and health sciences, фибрилляция предсердий, 0302 clinical medicine, регистр, RC666-701, Diseases of the circulatory (Cardiovascular) system, atrial fibrillation, Therapeutics. Pharmacology, treatment compliance, антитромботическая терапия

Access URL: http://www.rpcardio.com/jour/article/download/295/309
https://doaj.org/article/42023a2b56af4f3ea33974f0e7a0c0ab
https://doaj.org/article/ea4476ebf61143adafeb10a74d518d3a
https://core.ac.uk/display/87816501
https://doaj.org/article/42023a2b56af4f3ea33974f0e7a0c0ab
https://www.rpcardio.com/jour/article/download/295/309
http://www.rpcardio.com/jour/article/download/295/309
https://www.rpcardio.com/jour/article/view/295

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION

Authors: A. V. Rudakova, Vladimir Anatolyevich Parfenov

Source: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 3, Pp 275-282 (2015)

Subject Terms: анализ затраты-эффективность, варфарин, новые пероральные антикоагулянты, апиксабан, cost-effectiveness analysis, apixaban, RM1-950, acetylsalicylic acid, 3. Good health, novel oral anticoagulants, warfarin, 03 medical and health sciences, фибрилляция предсердий, 0302 clinical medicine, RC666-701, Diseases of the circulatory (Cardiovascular) system, atrial fibrillation, Therapeutics. Pharmacology, ацетилсалициловая кислота, 10. No inequality

Access URL: http://www.rpcardio.com/jour/article/download/233/243
https://doaj.org/article/68dc57b562194a789db462f64a160da7
https://doaj.org/article/0e2955a5cd7745999a647907f7925af9
https://www.rpcardio.com/jour/article/download/233/243
https://core.ac.uk/display/87816656
https://doaj.org/article/68dc57b562194a789db462f64a160da7
https://www.rpcardio.com/jour/article/view/233

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION

Authors: A. A. Kastanayan, E. A. Lipnitskaya, M. E. Statsenko, S. G. Kanorskiy, D. B. Goltyapin, E. D. Kosmacheva, N. V. Haylo

Source: Рациональная фармакотерапия в кардиологии, Vol 9, Iss 5, Pp 551-556 (2015)

Subject Terms: новые пероральные антикоагулянты, new oral anticoagulants, RM1-950, dabigatran etexilate, 3. Good health, 03 medical and health sciences, фибрилляция предсердий, 0302 clinical medicine, дабигатрана этексилат, профилактика инсульта, RC666-701, Diseases of the circulatory (Cardiovascular) system, atrial fibrillation, stroke prevention, Therapeutics. Pharmacology

Access URL: https://www.rpcardio.com/jour/article/download/232/242
https://doaj.org/article/5cc44adbbae74f068d1d2dfd33f7451a
https://doaj.org/article/e3ba39057517419fb98b67e4c943f292
https://www.rpcardio.com/jour/article/download/232/242
https://core.ac.uk/display/44489903
https://www.rpcardio.com/jour/article/view/232

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA

Authors: A. B. Prokofiev, V. A. Otdelenov, Dmitriy A. Sychev, R. E. Kazakov

Source: Рациональная фармакотерапия в кардиологии, Vol 9, Iss 5, Pp 525-531 (2015)

Subject Terms: 0301 basic medicine, anticoagulants, 0303 health sciences, vkorc1, варфарин, новые пероральные антикоагулянты, new oral anticoagulants, ces1, дабигатран, RM1-950, CYP2С9, 3. Good health, warfarin, VKORC1, 03 medical and health sciences, cyp2c9, RC666-701, фармакогенетика, CES1, Diseases of the circulatory (Cardiovascular) system, dabigatran, Therapeutics. Pharmacology, pharmacogenetics, антикоагулянты

Access URL: https://www.rpcardio.com/jour/article/download/220/230
https://doaj.org/article/189a689a3a01454b92e9d312b92fd397
https://doaj.org/article/21048b26926a41089aa3403d0faca643
https://www.rpcardio.com/jour/article/view/220
https://www.rpcardio.com/jour/article/download/220/230

РИВАРОКСАБАН ПРИ ТРОМБОЗЕ ЛЕВОГО ПРЕДСЕРДИЯ У ПАЦИЕНТА С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ ПРИ ПРОВЕДЕНИИ КАТЕТЕРНОЙ АБЛЯЦИИ

Source: Атеротромбоз, Vol 0, Iss 2, Pp 82-85 (2014)

Subject Terms: трепетание предсердий, тромбоэмболические осложнения, тромбоз левого предсердия, новые пероральные антикоагулянты, ривароксабан, Internal medicine, RC31-1245

File Description: electronic resource

Relation: https://www.aterotromboz.ru/jour/article/view/39; https://doaj.org/toc/2307-1109; https://doaj.org/toc/2658-5952

Access URL: https://doaj.org/article/4b9111756b854296aa9c954759af229e

БЕЗОПАСНОСТЬ АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ. КАК ОБЕСПЕЧИТЬ ПАЦИЕНТУ ОПТИМАЛЬНОЕ ЛЕЧЕНИЕ?

Source: Атеротромбоз, Vol 0, Iss 2, Pp 11-18 (2014)

Subject Terms: фибрилляция предсердий, антикоагулянтная терапия, новые пероральные антикоагулянты, апиксабан, Internal medicine, RC31-1245

File Description: electronic resource

Relation: https://www.aterotromboz.ru/jour/article/view/32; https://doaj.org/toc/2307-1109; https://doaj.org/toc/2658-5952

Access URL: https://doaj.org/article/97ffe2be6a9743bea28dec572977ed67

ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN ; ПЕРОРАЛЬНЫЕ АНТИКОАГУЛЯНТЫ В ЛЕЧЕНИИ ВЕНОЗНЫХ ТРОМБО- ЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ: ФОКУС НА АПИКСАБАН

Authors: M. Yu. Gilyarov, E. V. Konstantinova, М. Ю. Гиляров, Е. В. Константинова

Source: Meditsinskiy sovet = Medical Council; № 7 (2017); 56-62 ; Медицинский Совет; № 7 (2017); 56-62 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-7

Subject Terms: новые пероральные антикоагулянты, venous thromboembolism, pulmonary embolism, deep vein thrombosis, anticoagulants, vitamin K antagonist, direct oral anticoagulants, венозные тромбоэмболические осложнения, тромбоэмболия легочной артерии, тромбоз глубоких вен нижних конечностей, антикоагулянты, антагонисты витамина К

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1770/1714; Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol, 2012, 25: 235-42.; Bĕlohlavek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol, 2013, 18: 129-38.; Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet, 2012, 379: 1835-46.; Beckman MG, Hooper WC, Critchley SE, Ortel TL: Venous thromboembolism: a public health concern. Am J Prev Med, 2010, 38: 495-501.; Deitelzweig SB, Johnson BH, Lin J, Schulman KL: Prevalence of clinical venous thromboembolism in the USA: Current trends and future projections. Am J Hematol, 2011, 86: 217-220.; Cohen AT, Agnelli G, Anderson FA, et al. VTE Impact assessment group in Europe (VITAE): Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost, 2007, 98: 756-64.; Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология, 2010, 4(1) вып. 2: 3-37.; Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(Suppl): e419S-e494S.; The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Endorsed by the European Respiratory Society (ERS). Eur Heart J, 2014, 35: 3033-3069.; Holbrook A, Schulman S, Witt DM et al. Evidence-Based Management of Anticoagulant Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(Suppl): e152S-e184S.; Fang MC, Fan D, Witt DM et al. The Association of Warfarin Control With Pulmonary Embolism Mortality: The CVRN VTE Study. Circulation, 2013, 128: A12186.; Erkens PM, ten Cate H, Büller HR, Prins M.H. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One, 2012, 7: e42269.; Agnelli G, Buller HR, Cohen A et al. for the AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med, 2013, 369: 799-808.; Agnelli G, Buller HR, Cohen A, et al. for the AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med, 2013, 368: 699-708.; Raskob GE, Gallus AS, Sanders P, Thompson JR, Agnelli G, Buller HR, Cohen AT, Ramacciotti E, Weitz JI. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost, 2015 Dec 10, 115(4).; Richard H., White R.H. The epidemiology of venous thromboembolism. Circulation, 2003, 107(23 Suppl 1): I4-I8.; Lassen MR, Raskob GE, Gallus A et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet, 2010, 375(9717): 807-815.; Lassen MR, Gallus A, Raskob GE et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med, 2010, 363(26): 2487-98.; Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in in patients with atrial fibrillation: the Euro Heart Survey on atrial fibrillation. Chest, 2010, 138: 1093-1100.; Kaatz S, Kouides PA, Garcia DA et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol, 2012, 87(Suppl 1): S141-S145.; Bauer KA. Reversal of antithrombotic agents. Am J Hematol, 2012, 87(Suppl 1): S119-S126.; Geldhof V, Vandenbriele C, Verhamme P, Vanassche T. Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants Geldhof et al. Thrombosis Journal, 2014, 12: 21. http://www.thrombosisjournal.com/content/12/1/21.; Granger CB, Alexander JH, McMurray JJ et al. for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 365: 981-992.; Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Национальные рекомендации. Российский кардиологический журнал, 2014, 8(112): 7-37.; Douxfils J, Chatelain C, Chatelain B et al. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost, 2013, 110(2): 283-94.; Becker RC, Yang H, Barrett Y et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban – an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis, 2011, 32: 183-7.; Шаталова О.В. Клинико-экономический анализ применения апиксабана для лечения венозных тромбоэмболических осложнений. Рациональная фармакотерапия в кардиологии, 2015, 11(6): 601-606.

Availability: https://www.med-sovet.pro/jour/article/view/1770
https://doi.org/10.21518/2079-701X-2017-7-56-62

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION

Authors: A. V. Rudakova

Source: Рациональная фармакотерапия в кардиологии, Vol 11, Iss 1, Pp 60-62 (2015)

Subject Terms: фибрилляция предсердий, новые пероральные антикоагулянты, анализ затраты-эффективность, апиксабан, ривароксабан, дабигатран, варфарин, ацетилсалициловая кислота, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

File Description: electronic resource

Relation: http://www.rpcardio.ru/jour/article/view/61; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

Access URL: https://doaj.org/article/997e8ec90e104d8c9d9eb66dcca15a0d